newdrugapprovals.org
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab, MK 3222
Tildrakizumab (MK-3222) Company Merck & Co. Inc. Description Anti-IL-23 antibody Molecular Target Interleukin-23 (IL-23) Mechanism of Action Antibody Therapeutic Modality Biologic: Antibody Lat…